

D1
11. (Once amended) The method according to claim 1 or 2, wherein said HLA allele-specific forward primers and HLA allele-specific reverse primers are selected from the group consisting of:

SEQ ID NOS: 169-269.

REMARKS

With entry of this amendment, claims 1-15 are pending. Claim 11 is amended. Claims 16-28 are cancelled without prejudice to subsequent revival. For convenience, the Examiner's rejections are addressed in the order presented in the June 19, 2002, Office Action. Appendix A provides the version with markings to show changes made to the claims. Also for the Examiner's convenience, Appendix B is included listing all claims currently under examination.

I. Status of the claims

Claim 11 is amended to correct an obvious typographical error. This amendment adds no new matter.

II. Objections to the Specification

The Examiner objected to informalities in the specification and requested a new sequence listing for sequences on pages 48-55. Applicants submitted a separate amendment and sequence listing on August 20, 2002, to comply with the Examiner's request.

III. The claimed invention

The claimed invention is a novel method of identifying the HLA genotype of an individual. Generally speaking, HLA genes are made up of allele-specific sequences that vary between individuals, and locus-specific or conserved sequences that do not vary appreciably between individuals. Two different aspects of HLA genotype identification are claimed. In both, a DNA sample is first obtained from the individual.